Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pemigatinib

FDA-approved product (tablet, oral), marketed as Pemazyre.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Pemigatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cholangiocarcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pemigatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pemigatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

    NCT06022289 · start 2023-05-01

    Registered record
    Registry ID
    NCT06022289
    Conditions
    Solid Tumor; FGF Receptor Gene Mutation; FGF Amplification; FGF Receptor Gene Family Rearrangement; FGF Receptor Gene Translocation
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-05-01
    Completion
    2025-05-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor; FGF Receptor Gene Mutation; FGF Amplification; FGF Receptor Gene Family Rearrangement +1 more
    InterventionPemigatinib
    PhasePhase 2
    Registry statusUnknown

  • Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

    NCT05651672 · start 2022-12-02

    Registered record
    Registry ID
    NCT05651672
    Conditions
    Gastrointestinal Cancer
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-12-02
    Completion
    2026-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Cancer
    InterventionPemigatinib
    PhasePhase 2
    Registry statusRecruiting

  • Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

    NCT05565794 · start 2022-11-11

    Registered record
    Registry ID
    NCT05565794
    Conditions
    Intrahepatic Cholangiocarcinoma; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene Translocation
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2022-11-11
    Completion
    2025-03-27
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntrahepatic Cholangiocarcinoma; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene Translocation
    InterventionPemigatinib
    PhasePhase 2
    Registry statusTerminated

  • A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations

    NCT05560334 · start 2022-09-08

    Registered record
    Registry ID
    NCT05560334
    Conditions
    Breast Cancer
    Interventions
    Pemigatinib Pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-09-08
    Completion
    2025-09-08
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionPemigatinib Pill
    PhasePhase 2
    Registry statusUnknown

  • A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy

    NCT05559775 · start 2022-08-10

    Registered record
    Registry ID
    NCT05559775
    Conditions
    Gastrointestinal Cancer
    Interventions
    Pemigatinib Pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-08-10
    Completion
    2025-08-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Cancer
    InterventionPemigatinib Pill
    PhasePhase 2
    Registry statusUnknown

  • Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

    NCT05216120 · start 2022-06-14

    Registered record
    Registry ID
    NCT05216120
    Conditions
    Pancreas Cancer
    Interventions
    Pemigatinib 4.5 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2022-06-14
    Completion
    2025-08-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreas Cancer
    InterventionPemigatinib 4.5 MG
    PhasePhase 2
    Registry statusWithdrawn

  • Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

    NCT05267106 · start 2022-05-20

    Registered record
    Registry ID
    NCT05267106
    Conditions
    Glioblastoma; Adult-type Diffuse Gliomas
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2022-05-20
    Completion
    2024-12-17
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Adult-type Diffuse Gliomas
    InterventionPemigatinib
    PhasePhase 2
    Registry statusTerminated

  • Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

    NCT05253807 · start 2022-04-29

    Registered record
    Registry ID
    NCT05253807
    Conditions
    Non-Small Cell Lung Cancer (NSCLC)
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-04-29
    Completion
    2023-08-16
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer (NSCLC)
    InterventionPemigatinib
    PhasePhase 2
    Registry statusCompleted

  • Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

    NCT05004974 · start 2022-04-26

    Registered record
    Registry ID
    NCT05004974
    Conditions
    Advanced Non Small Cell Lung Cancer
    Interventions
    Sintilimab; Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-04-26
    Completion
    2025-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Non Small Cell Lung Cancer
    InterventionSintilimab; Pemigatinib
    PhasePhase 2
    Registry statusUnknown

  • A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

    NCT05287386 · start 2022-01-21

    Registered record
    Registry ID
    NCT05287386
    Conditions
    Advanced Non-Small Cell Lung Cancer
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-01-21
    Completion
    2025-01-21
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Non-Small Cell Lung Cancer
    InterventionPemigatinib
    PhasePhase 2
    Registry statusUnknown

  • The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

    NCT05159245 · start 2021-12-10

    Registered record
    Registry ID
    NCT05159245
    Conditions
    Advanced Cancer; Solid Tumor; Haematological Malignancy
    Interventions
    Alectinib; Cobimetinib; Vismodegib; Trastuzumab+Pertuzumab; Entrectinib; Atezolizumab; Vemurafenib; Regorafenib; Apalutamide; Abemaciclib; Tepotinib; Dabrafenib; Trametinib; Dabrafenib+Trametinib; Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-12-10
    Completion
    2026-11-25
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer; Solid Tumor; Haematological Malignancy
    InterventionAlectinib; Cobimetinib; Vismodegib; Trastuzumab+Pertuzumab +11 more
    PhasePhase 2
    Registry statusRecruiting

  • A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients

    NCT05210946 · start 2021-12-06

    Registered record
    Registry ID
    NCT05210946
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-12-06
    Completion
    2024-12-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionPemigatinib
    PhaseNot applicable
    Registry statusUnknown

  • A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

    NCT05202236 · start 2021-10-13

    Registered record
    Registry ID
    NCT05202236
    Conditions
    Gastric and Colorectal Cancer
    Interventions
    pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-10-13
    Completion
    2024-10-13
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric and Colorectal Cancer
    Interventionpemigatinib
    PhasePhase 2
    Registry statusUnknown

  • The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

    NCT04949191 · start 2021-07-08

    Registered record
    Registry ID
    NCT04949191
    Conditions
    Advanced Malignancies
    Interventions
    Pemigatinib; Retifanlimab; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-07-08
    Completion
    2024-04-11
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignancies
    InterventionPemigatinib; Retifanlimab; Pembrolizumab
    PhasePhase 2
    Registry statusTerminated

  • Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

    NCT04463771 · start 2021-01-26

    Registered record
    Registry ID
    NCT04463771
    Conditions
    Endometrial Cancer
    Interventions
    retifanlimab; epacadostat; pemigatinib; INCAGN02385; INCAGN02390
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-01-26
    Completion
    2026-05-29
    Enrolment
    206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Cancer
    Interventionretifanlimab; epacadostat; pemigatinib; INCAGN02385 +1 more
    PhasePhase 2
    Registry statusCompleted